Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2021

View Archived Issues

Cancer vaccine CVD908ssb-TXSVN enters phase I study for multiple myeloma

Vidutolimod to be studied in triple-negative breast cancer and non-melanoma skin cancer

First patient dosed with CIT-013, a first-in-class antagonist targeting NETs

Complexes cross BBB, knock down CNS genes in rodents

Collaboration announced for phase II study of larazotide for COVID-19-derived MIS-C

Joint venture announcement behind AR-035 and AR-882 development in China

DNMT3a and DNA methylation alterations in the nucleus accumbens are involved in PTSD-like behavior

Sichuan Kelun-Biotech Biopharmaceutical patents TGFR1 inhibitors

Jiangsu Simcere Pharmaceutical presents BTK and JAK3 inhibitors

Enanta Pharmaceuticals synthesizes new antiviral compounds

Sirnaomics describes new siRNAs targeting SARS-CoV-2

Istari Oncology expands LUMINOS-103 trial of PVSRIPO to include HNSCC

Transcenta begins phase II trial of TST-001 in solid tumors

Phase I study of Alzheimer's disease candidate AL-001 to begin in September

Preclinical toxicology study supports development of antidiarrheal lechlemer

Ganaxolone reduces seizure frequency in tuberous sclerosis complex patients

HER2 expression is a prognostic factor in DCIS

Pirfenidone shows favorable effects in patients with HFpEF

ExeVir's COVID-19 treatment and prophylactic XVR-011 enters clinical study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...